Welcome to our dedicated page for Silo Pharma news (Ticker: SILO), a resource for investors and traders seeking the latest updates and insights on Silo Pharma stock.
Silo Pharma, Inc. (Nasdaq: SILO) regularly issues news updates that reflect its dual identity as a developmental-stage biopharmaceutical company and a cryptocurrency treasury company. Its press releases highlight progress in drug development for stress-induced psychiatric disorders, chronic pain, and central nervous system diseases, alongside announcements about its evolving digital assets treasury strategy.
On the biopharmaceutical side, Silo’s news flow centers on SPC-15, an investigational intranasal serotonin 5-HT4 receptor agonist being developed for PTSD and stress-induced anxiety. Recent releases describe IND-enabling toxicology and toxicokinetic work, large animal safety studies, drug-device evaluations of a soft mist nasal spray system, and plans for Phase 1 single ascending dose and multiple ascending dose studies. The company also reports on regulatory strategy, including its intention to pursue the FDA’s 505(b)(2) pathway, and on collaborations with organizations such as Allucent and Columbia University.
News items also cover Silo’s broader pipeline, including SP-26 for fibromyalgia and chronic pain and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Investors following SILO news can expect updates on preclinical data, clinical trial preparations, intellectual property expansion, and strategic academic and CRO partnerships.
In parallel, Silo’s releases describe the launch and build-out of its digital assets treasury. Announcements detail initial purchases of Bitcoin, Ethereum, Solana, and ResearchCoin, the establishment of a Crypto Advisory Board, engagement of Fireblocks for institutional-grade custody and infrastructure, and allocation to the Alphaledger T12 Fund for tokenized real-world asset exposure on the Solana blockchain. Additional disclosures include software and domain acquisitions related to crypto applications and updates on treasury diversification objectives.
Visitors to the SILO news page can use this stream of company-issued information to track clinical milestones, regulatory steps, capital markets activity, and digital asset strategy developments over time.
Silo Pharma, a biopharmaceutical company focusing on psychedelic research, announced that James Kuo, M.D., will present at the 3rd Annual Psychedelic Therapeutics and Drug Development Conference on May 15-16, 2023, in Burlingame, CA. Dr. Kuo's presentation, titled ‘The Ketamine Endgame,’ will explore the potential of ketamine for treating conditions like treatment-resistant depression, anxiety, and pain. Three of the company's drug candidates utilize ketamine: SP-26 for fibromyalgia, SPC-14 for Alzheimer's-related dementia, and SPC-15 for stress and PTSD. The conference aims to discuss challenges and advancements in psychedelic research for various health conditions including depression, PTSD, and pain management.
Silo Pharma (Nasdaq:SILO) has announced the development of SPC-15, a novel drug formulation targeting stress, anxiety, and PTSD. This initiative is part of a research agreement with Columbia University and aims to explore dose strengths and delivery methods for this potential treatment. Current research suggests that SPC-15 could effectively address cognitive impairment and other stress-related disorders. The drug's development aligns with alarming statistics: over 300 million people globally suffer from anxiety disorders, while approximately 12 million U.S. adults experience PTSD. The market for anxiety and depression treatments is projected to reach $13 billion by 2027. Additionally, Silo Pharma has secured a U.S. patent for SPC-15 as a treatment method for stress-induced disorders in females.
FAQ
What is the current stock price of Silo Pharma (SILO)?
What is the market cap of Silo Pharma (SILO)?
